Epidemiological and general survival characteristics of malign plevral mesothelioma patients in Ege University Hospital
Abstract
Aim: Malignant pleural mesothelioma is a fatal disease with poor prognosis. Mean survival in mesothelioma varies between 4-18 months. Because of the high mortality rate despite all the treatments, all the known treatments can be applied to the patients. Therefore, according to tumor stage, patient performance, histological subtype; multimodal treatment regimens including surgery, chemotherapy and radiotherapy.
Materials and Methods: In this study, epidemiological and general survival characteristics of 241
malignant pleural mesothelioma patients in the database of Ege University Hospital between 1992 and
2017 will be compared statistically with global results and malignant pleural mesothelioma data will be
evaluated.
Results: Of the total 240 patients enrolled, 154 (64%) were male and 86 (36%) were female. When
the survival effect of the treatments was evaluated, it was seen that the best result (median survival 24
months, 5-year survival 16%, p < 0.001) was achieved with combined therapy. When the effect of
pathological subtypes on survival was examined, it was found that epitheloid mesothelioma subtype
showed significantly better survival.
Conclusion: The most successful results in malignant mesothelioma are obtained with combined
therapies. Survival is prolonged in patients with chemotherapy, radiotherapy and surgical treatment.
We believe that as the number of patients increases and with a regular registration system, we can
achieve healthier results in the years to come.
Keywords
References
- Robinson BWS, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397–08.
- Okabe K. Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma. AnnTranslMed. 2017;5:233.
- Türkiye Mezotelyoma Çalışma Grubu. Malign Plevral Mezotelyoma Türkiye Standartlar Rehberi. Eskişehir: ESOGÜ-APKAM; 2014.
- Light RW. Tumors of the pleura. In: Murray JF, Nadel JA, eds. Textbook of respiratory medicine, vol 2. Philadelphia: Saunders, 1994:2222-30.
- Steele JP, Klabatsa A, Fennell DA, et al: Prognostic factors in mesothe- lioma. Lung Cancer 2005;49(Suppl 1):49-5.
- Opitz I, Sigrist B, Hillinger S, et al. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. Lung Cancer 2007;56:327-36.
- Beebe-Dimmer JL, Fryzek JP, Yee CL, et al: Mesothelioma in the United States: A Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol 2016;8:743-50.
- Maggioni C, Barletta G, Rijavec E, et al: Advances in treatment of mesothelioma. Expert Opin Pharmacother 2016;17:1197-205.
- Rusch V, Baldini EH, Bueno R, et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11- 2012, Boston, Mass. J Thorac Cardiovasc Surg 2013;145:909-10.
- Wald O, Sugarbaker DJ. Perspective on malignant pleural mesothelioma diagnosis and treatment. Ann Transl Med 2016;4:120.
- Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 2012; 1: 491-6.
- Türkiye Asbest Kontolü Stratejik Planı. Türkiye Mezotelyoma Çalışma Grubu; 2013.
- Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: Experience with 29 patients. Thorax 1976; 31: 15–24.
- International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995; 108: 1122–8.
Ege Üniversitesi Hastanesi malign plevral mezotelyoma hastalarının epidemiyolojik ve genel sağ kalım özellikleri
Abstract
Amaç: Malign plevral mazotelyoma (MPM) kötü prognozlu ölümcül bir hastalıktır. MPM için ortalama sağ kalım 4-18 ay arasında değişmektedir. MPM’de tüm tedavilere rağmen yüksek mortalite görüldüğünden, elimizdeki bilinen tüm tedaviler hastalara uygulanabilmektedir. Bu nedenle tümör evresine, hasta performansına, histolojik alt tipine göre; cerrahi, kemoterapi, radyoterapiyi içeren multimodal tedavi rejimleri söz konusu olmaktadır.
Gereç ve Yöntem: Bu çalışmada Ege Üniversitesi Hastanesi veri tabanındaki 1992-2017 yılları arası 241 malign plevral mezotelyoma hastasının epidemiyolojik ve genel sağ kalım özellikleri istatistiksel açıdan global sonuçlarla karşılaştırılacak ve malign plevral mezotelyoma verileri değerlendirilecektir.
Bulgular: Kayıtlı toplam 240 hastanın 154’ü (%64) erkek, 86’sı (%36) kadındı. Yas ortalaması 56 (19-78) idi. Sağ kalım değerlendirilmesinde yapılan tedavilerin sağ kalıma etkisine bakıldığında en iyi sonucun (ortalama sağ kalım 24 ay, beş yıllık yaşam %16, p˂0.001) kombine tedavi ile sağlandığı görülmüştür. Patolojik alt grupların sağ kalıma etkisine bakıldığında (Grafik 5) epiteloid mezotelyoma alt tipinin de anlamlı olarak daha iyi yaşam süresi gösterdiği bulunmuştur (ortalama sağ kalım 24 ay, beş yıllık yaşam %15, p<0,001).
Sonuç: Malign mezotelyomada en başarılı sonuçlar kombine tedavilerle elde edilmektedir. Kemoterapi, radyoterapi ve cerrahi tedavinin beraber uygulanabildiği hastalarda sağ kalım uzamaktadır. Hasta sayısı arttıkça ve düzenli bir kayıt sistemi ile ilerleyen yıllarda daha sağlıklı sonuçlar verebileceğimizi düşünüyoruz.
Keywords
References
- Robinson BWS, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397–08.
- Okabe K. Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma. AnnTranslMed. 2017;5:233.
- Türkiye Mezotelyoma Çalışma Grubu. Malign Plevral Mezotelyoma Türkiye Standartlar Rehberi. Eskişehir: ESOGÜ-APKAM; 2014.
- Light RW. Tumors of the pleura. In: Murray JF, Nadel JA, eds. Textbook of respiratory medicine, vol 2. Philadelphia: Saunders, 1994:2222-30.
- Steele JP, Klabatsa A, Fennell DA, et al: Prognostic factors in mesothe- lioma. Lung Cancer 2005;49(Suppl 1):49-5.
- Opitz I, Sigrist B, Hillinger S, et al. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. Lung Cancer 2007;56:327-36.
- Beebe-Dimmer JL, Fryzek JP, Yee CL, et al: Mesothelioma in the United States: A Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol 2016;8:743-50.
- Maggioni C, Barletta G, Rijavec E, et al: Advances in treatment of mesothelioma. Expert Opin Pharmacother 2016;17:1197-205.
- Rusch V, Baldini EH, Bueno R, et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11- 2012, Boston, Mass. J Thorac Cardiovasc Surg 2013;145:909-10.
- Wald O, Sugarbaker DJ. Perspective on malignant pleural mesothelioma diagnosis and treatment. Ann Transl Med 2016;4:120.
- Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 2012; 1: 491-6.
- Türkiye Asbest Kontolü Stratejik Planı. Türkiye Mezotelyoma Çalışma Grubu; 2013.
- Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: Experience with 29 patients. Thorax 1976; 31: 15–24.
- International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995; 108: 1122–8.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Supplement |
| Authors | |
| Publication Date | December 31, 2019 |
| Submission Date | February 15, 2019 |
| Published in Issue | Year 2019Volume: 58 Suppl: 2 (Oncology) |
